+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06768489

Study of JNJ-79635322 With Daratumumab and Optional Lenalidomide or Pomalidomide for Multiple Myeloma, AL Amyloidosis, and High-risk Smoldering Multiple Myeloma

Led by Janssen Research & Development, LLC · Updated on 2026-09-25

276

Participants Needed

16

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and optimal dosing of JNJ-79635322 combined with daratumumab, with or without lenalidomide or pomalidomide, in participants with multiple myeloma, newly diagnosed amyloid light chain AL amyloidosis, and high-risk smoldering multiple myeloma. This phase 1b trial aims to find recommended phase 2 doses RP2Ds and schedules for these combination treatments to better understand their effects and safety profiles. Participants receive JNJ-79635322 subcutaneously combined with daratumumab also given subcutaneously and may also receive oral lenalidomide or pomalidomide depending on their disease status and prior treatments. The study has two parts Part 1 involves dose escalation and de-escalation to determine safe and effective dosing, while Part 2 involves dose expansion to further evaluate safety and tolerability at the chosen doses in specific disease subgroups. Throughout the study, participants are closely monitored with assessments including dose-limiting toxicity within 28 days, adverse events and laboratory abnormalities over more than three years, and various response rates. Blood levels of the drugs and immune response markers are also measured. The study tracks participants disease responses and drug pharmacokinetics to gather comprehensive safety and effectiveness data over an extended period.

CONDITIONS

Brief Title

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here